Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for children and to improve patient outcomes.

Women sitting in front of huts, traditional village in Southeast Asia © Pearl Gan

Scrub typhus is an acute febrile illness caused by intracellular bacteria from the genus Orientia. It is estimated that one billion people are at risk, with one million cases annually mainly affecting rural areas in Asia-Oceania. Scrub typhus is difficult to diagnose clinically without laboratory tests because it lacks reliable distinguishing features that differentiate it from other febrile illnesses prevalent in the endemic areas, such as typhoid fever, dengue fever and malaria. This difficulty in diagnosis is one of the main reasons for the current limited epidemiological knowledge on scrub typhus.

With scant and scattered data, it is difficult to identify the most at-risk populations, the regional distribution, and the optimal treatments to support disease control efforts. National treatment recommendations for scrub typhus vary or are simply not stated, and the absence of WHO recommendations illustrates the lack of high-quality supportive evidence for optimal treatments.

Researchers concluded there is substantial value in developing an IPD platform that will facilitate pooling and harmonisation of currently scattered data and enable in-depth investigation of priority research questions that can ultimately inform clinical practice and improve health outcomes for scrub typhus patients. The authors have called for scrub typhus to be recognised as a neglected tropical disease (NTD) by the WHO and the research community, which will help to increase awareness of the disease.

“The heterogeneous nature of the available data reflects the absence of consensus in treatment and research methodologies and poses a significant barrier to aggregating information across available published data without access to the underlying individual participant-level data (IPD). There is likely to be a substantial amount of data available to address knowledge gaps.” First author Kartika Saraswati

Read the publication 'Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform' on the PLOS Neglected Tropical Diseases website

The full story is available on the IDDO website

Similar stories

A new WWARN study supports safety of WHO recommended malaria treatment to advance elimination and reduce spread of artemisinin resistance

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Routine surveillance data can provide an early warning system for antimalarial resistance in pre-elimination areas in Africa

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

OUCRU presents a new virtual exhibition: Digital Diaries, Voices from the Pandemic, COVID-19 experiences in Asia

This online exhibition showcases short films and photographs created by health-care workers and community members and documents the socio-cultural impact of the COVID-19 pandemic in Indonesia, Nepal and Vietnam.

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

FORESFA and VIE project meetings

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.